| Mar H. Maeda successfully develops commercially viable BioBran MGN-3 by using special extraction methods on rice bran at Daiwa Pharmaceutical in Japan. This proves much more potent than the AHCC he developed a few years earlier. Clinical trials with this new generation arabinoxylan compound begin |
|
| Immunomodulatory and anti-cancer properties of MGN-3, a modified xylose from rice bran, in 5 patients with breast cancer: presentation by M. Ghoneum of UCLA/Drew University at the American Association for Cancer Research at Baltimore, Maryland, USA. NK cell activity substantially increased within just a couple of weeks taking MGN-3 at a dose of 3g /day. Two patients who participated early in the study (6-8 months) went into complete remission. . |
|
| NK immunomodulatory function in 27 cancer patients by MGN-3, a modified arabinoxylan from rice bran: presentation by M. Ghoneum at the 87th Annual Meeting of the American Association for Cancer research entitled. 7 patients had breast cancer, prostate; 8 multiple myeloma (MM); 3 leukemia and 2 cervical. All patients taking conventional treatments as well as 3g MGN-3 per day. All patients had significant rises in NK cell activity when taking MGN-3 (100 – 537% increases). |
|
| Acute Oral Toxicity Test at the AMA Laboratories, New York, USA (Ref: WP96-BERN1/LD504881.DP) Animal Experiment involving rats to determine any potential toxicity of MGN-3. Above material can be classified as non-toxic according to the reference. LD50 > 36.0g / kg. |
|
| Effect of MGN-3 on human natural killer cell activity and interferon-g synthesis in vitro: abstract of presentation given by M. Ghoneum at the ASBMB/ASIP/AAI joint meeting in New Orleans entitled. Conclusion was that MGN-3 is a potent Biological Response Modifier (BRM) as indicated by the significant increases in human NK cell activity at 16 hours post exposure through the production of IFN-G. MGN-3 also had direct anti-cancer activity in vitro. |
|
| Anti-HIV activity by MGN-3 in vitro: abstract of presentation given by M. Ghoneum at the 11th International Conference on AIDS in Vancouver. Conclusion: MGN-3 possesses a potent effect against syncytia formation by HIV and may be of potential value in therapy for HIV infection. |
|
| The effect of MGN-3, an arabinoxylan compound, on serum lipids in streptozotocin induced diabetic rats: abstract presented by Ohara, Tabuchi and Maeda (Japan) at the 38th Annual Meeting of The American College of Nutrition. MGN-3 was shown to reduce the rise in serum triglyceride and total cholesterol in diabetic rats indicating that it may be useful in the treatment of diabetes. |
|
| Anti-HIV activity in vitro of MGN-3, an activated arabinoxylan from rice bran: paper by M. Ghoneum in the Biochemical and Biophysical Research Communications Journal 243, 25-29 (1998), Article No. RC978047. This is a detailed write up of the abstract Ghoneum presented in July 1996 at the International Conference on AIDS in Vancouver |
|
| Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (MGN-3): paper by M. Ghoneum in the International Journal of Immunotherapy XIV (2) 89-99 (1998). Study involved 24 individuals taking MGN-3 at 3 different concentrations. NK cell activity was significantly increased after 1 week and peaked at 2 months. Also measured was a significant increase in interferon-g. |
|
| MGN-3 immunotherapy for the treatment of cancer: abstract presented by M. Ghoneum at the First International Symposium on Disease Prevention by IP6 and Other Rice Components in Japan. The 10 cancer patients in the study showed large increases in NK cell activity and elevated T and B cell function by its ability to produce cytokines such as TNF-a and IFN-g. |
|
| Human NK activity and synergism of a low dose of IL2 and a modified rice bran arabinoxylan on a generation of TNF: presentation by M. Ghoneum and A. Gewet at the Conference of Anti-Aging Mechanism. |
|
| NK cell activity by MGN-3: presentation by M. Ghoneum at the 26th Academy of Alternative Medicine of Cancer in Los Angeles. |
|
| Immunopotentiation by utilization of MGN-3 tissue: presentation by M. Ghoneum at the Congress on Anti-Aging Medicine in Nevada. |
|
| NK immunorestoration of cancer patients by MGN-3, a modified arabinoxylan rice bran (study of 32 patients up to 4 years): paper by M. Ghoneum given at the 6th International Congress on Anti-Aging & Bio-Medical Technologies. Conclusion: MGN-3 is a potent biological response modifier in its ability to significantly increasing the activity of NK cells in both animals and humans. The mechanism by which it does this is firstly that it increases the granularity of the NK cells and secondly it elevates cytokine production. |
|
| Evalution of processed vegetable polysaccharide food BioBran on superoxide scavenging activity: presentation by K. Tazawa, Toyama Medical and Pharmaceutical University, and H. Maeda, Daiwa Pharmaceutical Co. Ltd., at the 3rd JsoFF Conference. |
|
| A case study of supplementary application of rice bran Arabinoxylan (MGN-3) to bone metastasis from lung cancer: presentation by T. Sobajima and H. Maeda at the 2nd Conference of Japanese Association for Alternative, Complementary and Traditional Medicine (JACT), Tokyo Japan. Sobajima T., Hoshigaoka Welfare Annuity Hospital and Maeda H., Daiwa Pharmaceutical Co. Ltd., Tokyo. |
|
| Evaluation of MGN-3 (BioBran) on superoxide scavenging activity: presentation by K. Tazawa, H. Namikawa, S. Oida, K. Ito, M. Yatsuzuka, J. Koike, H. Maeda at the 6th Japanese Conference on Cancer Prevention, Tokyo Japan. Toyama Medical University. |
|
| Evaluation of MGN-3 (BioBran) with activation function of NK cell activity on superoxide scavenging activity: presentation by K. Tazawa, H. Namikawa, S. Oida, K. Ito, M. Yatsuzuka, J. Koike, M. Masada and H. Maeda at the 12th Japanese Conference on Bio Therapy, Yokohama Japan. Toyama Medical University, Chiba University and Daiwa Pharmaceutical. |
|
| Application of modified rice bran dietary fiber to diabetes and taste preference in streptozotocin-included diabetic rats: presentation by I. Ohara, K. Onai and H. Maeda at the 2nd International Conference on Food Factors, Kyoto, Japan. Laboratory of Nutrition, Kobe Women's University, and Daiwa Pharmaceutical. |
|
| Immunostimulation and Cancer Prevention: presentation by M. Ghoneum at the 7th International Congress on Anti-Aging & Biomedical Technologies, Las Vegas, USA. Drew University. |
|
| Physiological Activator, Oryza Sativa L. Arabinoxylan Derivative (MGN-3): presentation by H. Maeda at the 6th Japanese Congress on Mibyo System, Hiroshima Japan. Daiwa Pharmaceutical Co. Ltd. |
|
| Production of TNF-a and IFN-g From human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran: paper by Ghoneum and Jewett in Cancer Detection and Prevention, 24 (4): 314-324 (2000). This study showed that MGN-3 is a potent TNF-a producer and that it induces the TNF-a secretion in a dose dependent manner. Also, a combination of MGN-3 and IL-2 resulted in a synergistic induction of TNF-a and IFN-g secretion. MGN-3 appears to increase the expression of CD69 activation antigen. |
|
| Effects of modified rice bran on serum lipids and taste preference in streptozotocin-induced diabetic rats: paper by Ohara, Agr, Tabuchi, Onai and Econ from Kobe Women’s University in Kobe Japan in the Journal Of Nutritional Research, Vol. 20, No. 1, pp.59-68, 2000. The study was to determine whether the administration of MGN-3 could improve streptozotocin-induced diabetes. Results: serum triglycerides and total cholesterol decreased, and polyuria and taste was improved |
|
| The Effect of MGN-3 on cisplatin and adriamycin induced toxicity in the rat: paper by Jacoby, Wnorowski, Sakata and Maeda published in the American Society for Pharmacology and Experimental Therapeutics, Boston, USA. Conclusion: MGN-3 protects rates given an acutely toxic dose of cisplatin or adriamcyin. This indicates that the MGN-3 may well be good at improving the quality of life in patients receiving chemotherapy and may be a useful adjunct, therefore, to cancer chemotherapy. Product Safety Lab. and Daiwa Pharmaceutical Co. Ltd. |
|
| Inhibitory effects of MGN-3 (modified Arabinoxylan from rice bran) on free radical: presentation by T. Saito, H. Ohkami, K. Tsukada, K. Tazawa, H. Namikawa, S. Oida, J. Koike, M. Yatsuzuka, M. Masada, and H. Maeda at the 59th Annual Meeting of the Japanese Cancer Association, Yokohama Japan. Toyama Medical University, Chiba University and Daiwa Pharmaceutical. |
